Terns Pharmaceuticals Inc.
Terns Pharmaceuticals, Inc. Announces Stockholder Voting Results for 2024 Annual Meeting
Summary
On June 10, 2024, Terns Pharmaceuticals, Inc. held its 2024 Annual Meeting of Stockholders, where stockholders voted on two proposals. Proposal 1 involved the election of two Class III directors, with Jeffrey Kindler receiving 45,958,352 votes for and 6,735,358 votes withheld, and Amy Burroughs receiving 52,570,019 votes for and 123,691 votes withheld. Proposal 2 involved the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which received 57,570,954 votes for, 23,950 votes against, and 229,927 abstentions.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement